Abstract. Previous studies have demonstrated that the conditionally replicative adenovirus Ad5¢24 is a powerful cytolytic agent against glioma selectively affecting cells with a defective p16/Rb/E2F pathway. The p53 protein is also known to be an apoptotic factor for glioma cells. In this study, we examined the simultaneous delivery of the combination of exogenous p53 and Ad5¢24 adenovirus in glioma cells. Infecting cells with low doses of adenovirus p53 and Ad5¢24 resulted in an additive effect on cell death. The cell death induced by both agents was independent of the p53 status of cells. Flow cytometry revealed that the potent anti-tumor effect induced by the mixture of Ad5CMV-p53 and Ad5¢24 adenoviruses was due to a combination of apoptosis and cell lysis. Our results indicate that Ad5CMV-p53 enhances the oncolytic effect of the Ad5¢24 adenovirus, and the combination of adenovirus Ad5¢24 and Ad5CMV-p53 may thus be a potential therapeutic tool for gliomas.
Introduction
Malignant gliomas are the most common primary brain tumors in humans, and highly resistant to all current therapies, including widely investigated approaches to gene therapy. At the molecular level, glioblastomas are highly heterogeneous tumors, as several populations of cells with different gene abnormalities co-exist within a given tumor (1) . Secondary glioblastomas that develop from pre-existing low-grade astrocytomas frequently contain p53 mutations (1) , and abnormalities of the p16/Rb/E2F pathway are present in most gliomas (2, 3) .
Previous studies have demonstrated that the transfer of exogenous wild-type p53 cDNA causes apoptosis in glioma cells expressing endogenous mutant p53, but not in cells expressing endogenous wild-type p53 (4, 5) . However, only 50% of gliomas exhibit mutant p53, and the mutant cell population usually constitutes <30% of tumor mass (6) .
More than 90% of malignant gliomas exhibit abnormalities in the p16/Rb/E2F pathway (7) . The adenovirus Ad5¢24 carries a 24-bp deletion in the E1 region corresponding to amino acids 122-129 specific for binding the Rb protein. This virus produces an anti-glioma effect in vitro and in vivo in tumors with altered p16/Rb/E2F pathway (8) . The conditionally replicative adenoviruses (e.g. Ad5¢24 and ONYX-15) kill tumor cells selectively, and their replication leads to amplification of their oncolytic potential. Considerable preclinical data support this notion (8) (9) (10) (11) . In this study, we tested if the combination of an apoptotic molecule (p53) with an oncolytic adenovirus (Ad5¢24) could have an additive effect on cell death in malignant glioma cells.
Immunoblot analysis. Western blot analysis was performed as described previously (4) . Briefly, U-87 MG cells were infected with 20 MOI of Ad5CMV-pA, Ad5¢24, Ad5CMV-p53, Ad5¢24+Ad5CMV-p53 or mock infected. After 72 h, cells were collected and lysed with RIPA-A buffer in the presence of protease inhibitors. Protein (20 μg) from each sample was fractionated by SDS-PAGE and transferred to a nitrocellulose membrane. The membrane was probed with p53 antibody (diluted 1:2000) or anti-human ß-actin (diluted 1:500). The secondary antibodies were horseradish appropriate conjugates. The membranes were developed according to ECL protocol (Amersham).
Viability assay. Cell viability was assessed by both crystal violet and trypan blue exclusion test. a) Crystal violet: Monolayers of human glioma cells or normal human fibroblasts were infected at the indicated MOI with Ad5¢24 (1, 2, 5, 10 and 20 MOI) AdCMV-p53 (20 MOI) and their combination or UV-inactivated Ad5¢24 (at different MOIs mentioned above). Viable cells were stained with crystal violet when 5 MOI of Ad5¢24 produced >75% of the cytopathic effect.
b) Trypan blue exclusion test: Cell viability assessment of human glioma cells or normal human fibroblasts with trypan blue exclusion test. Cells were infected at different MOI of 5 and 10 plaque-forming units (pfu) per cell of Ad5¢24, 20 pfu/cell of Ad5CMV-p53, 5 and 10 pfu/cell of UVinactivated Ad5¢24, or mock infected, and cell viability was measured by trypan blue exclusion test. Each assay was carried out at least 3 times and is represented as cell viability relative to mock-treated cells (equal to 100%). Note that for U-251 MG, both the crystal violet and trypan blue exclusion tests were performed at day 5 after infection, while for U-87 MG the assays were performed at day 8 after infection. As expected, no cytotoxicity was observed for the human fibroblast cells (HFK-2 cells; assays were performed 8 days after infection).
Replication assay. U-87 MG cells were infected with 10 MOI of Ad5¢24 adenovirus. Cells were collected 3 days after infection and freeze-thawed 3 times. Supernatant was collected, and the TCID 50 method was used to determine viral replication. Briefly, 293 cells were seeded to 96-well plates and infected with the viral supernatant at different dilutions after 24 h. Ten days after infection, cells were observed under a light microscope to assess the cytopathic effect.
Flow cytometric analysis of DNA content. Cells were infected at MOI of 10 pfu/cell of Ad5¢24, 20 pfu/cell of Ad5CMV-p53 or mock infected. When cytotoxicity was observed (5 days for U-251 MG or 8 days for U-87 MG), they were trypsinized, fixed in 70% cold ethanol, and incubated with propidium iodide (50 mg/ml) and ribonuclease A (20 mg/ml) for 20 min at 37˚C and processed through a FACS. At least 10,000 events per sample were analyzed, and fluorescein isothiocyanate fluorescence was collected with a 525-nm bandpass filter. Coulter's cytologic program was used to analyze the data, and the mean peak fluorescence was determined for each histogram.
Results
Transfer of exogenous p53 to human glioma cells. We used the Ad5CMV vector to transfer p53 to glioma cell lines (U-87 MG and U-251 MG) and assessed the expression of exogenous proteins by the cells with Western blot analysis ( Fig. 1 ; data shown for U-87 MG). The amount of exogenous p53 protein expressed was at least 3-fold higher than the amount of the endogenous counterpart. Infection of glioma cells with both adenoviruses (oncolytic Ad5¢24 and Ad5CMV-p53) resulted in over-expression of the p53 protein at the same levels as Ad5CMV-p53 alone.
Cell viability. For the cell viability experiments, two human glioma cell lines (U-87 MG and U-251 MG) were infected with Ad5¢24, Ad5CMV-p53 or ultraviolet (UV)-inactivated Ad5¢24 adenoviruses and their combination at doses of 1, 2, 5, 10 and 20 MOI for Ad5¢24 and 20 MOI for Ad5CMV-p53. Cell viability was first assessed by crystal violet assay, then quantified with the trypan blue exclusion test. Both techniques showed a consistent dose-response effect of Ad5¢24 alone or in combination with Ad5CMV-p53 on the two glioma cell lines (Fig. 2) . The cytotoxic effect was more pronounced and exhibited earlier when the combination of the two viruses was used. Cultures were monitored every day by light microscopy, and a weak cytopathic effect was evident at day 3 post-infection. U-251 MG demonstrated a strong cytopathic effect at 5 days post-infection and U-87 MG at 8-9 days post-infection. The cytopathic effect was evidenced by the detachment of the cultures and formation of rounded unhealthy cells (data not shown). Furthermore, the transfer of Ad5¢24 and Ad5CMV-p53 resulted in a high percentage of cell death in U-87 MG, a p53-resistant glioma cell line (Fig. 2a) , as monitored by staining with crystal violet. In addition, the transfer of Ad5¢24 did not interfere with the apoptotic properties of exogenous wild-type p53 in U-251 MG cells, but resulted in an additive cytotoxic effect (Fig. 2a) . The cytopathic effect was noticeable with the combination of 5 MOI of Ad5¢24 and 20 MOI of Ad5CMV-p53 on the third day for U-251 MG and on the sixth day for U-87 MG. This effect was >75% at 5 and 8 days post-infection for U-251 MG and U-87 MG, respectively. Trypan blue exclusion tests further showed that the decreased viability observed in the crystal violet assays was highly reproducible and dosedependent in the cell lines tested (Fig. 2b) . Infection of U-87 MG for 8 days with 20 MOI of Ad5CMV-p53 did not result in substantial growth inhibition since 95% of cells remained viable relative to mock-infected cells (100%) (Fig. 2b) . However, infection of the above cell line with 5 or 10 MOI of Ad5¢24 resulted in 60% and 88% of growth inhibition, respectively, 8 days post-infection. Cell viability of U-87 MG infected with both Ad5¢24 (5 and 10 MOI) and Ad5CMV-p53 (20 MOI) 8 days post-infection was demonstrated to be 20% and 5%, respectively. Growth inhibition of U-87 MG by both viruses was not observed when Ad5¢24 was first UV-inactivated, then added to the cell cultures. This experiment showed that the replication of Ad5¢24 was the initial event that triggered cell death, and became more pronounced when Ad5CMV-p53 was added to the cell cultures simultaneously. Infection of U-251 MG for 5 days with 20 MOI of Ad5CMV-p53 resulted in 40% growth inhibition, an expected result since the U-251 MG cell line was a p53-mutated cell line and the exogenous p53 provoked apoptosis (Fig. 2b) . Infection of the above cell line with 5 or 10 MOI of Ad5¢24 resulted in 65% and 85% growth inhibition, respectively, 5 days post-infection. Cell viability of U-251 MG infected with both Ad5¢24 (5 and 10 MOI) and Ad5CMV-p53 (20 MOI) 5 days post-infection was demonstrated to be 15% and 5%, respectively. Growth inhibition of U-251 MG by both viruses was not observed when Ad5¢24 was first UV inactivated, then added to the cell cultures. This experiment showed that the transfer of Ad5¢24 did not interfere with the apoptotic properties of exogenous wild-type p53 in U-251 MG cells, but resulted in an additive cytotoxic effect (Fig. 2b) . It is well established that Ad5¢24 exhibits this potent oncolytic effect due to its ability to replicate in cancer cells with alterations in the p16/Rb/E2F pathway (8, 11) . In order to examine if Ad5¢24 replication and p53 over-expression affected normal cells, normal human kidney fibroblasts (HFK) were grown as a low confluency monolayer and arrested by serum starvation. The arrested cells were infected with Ad5CMV-p53, Ad5¢24 (5 and 10 MOI) and their combination and monitored every day for 8 days. Most cells retained their morphology and were attached to the culture dishes by the end of the experiment. These results were quantified by trypan blue viability assay and are shown in Fig. 2b . There were no significant differences in the viability of cells infected with Ad5CMV-p53, Ad5¢24 (5 and 10 MOI) and their combination. These results show that the oncolytic Ad5¢24 cannot replicate in normal quiescent cells, and p53 overexpression did not affect the growth status of such cultures. This observation is important when considering this combination gene effect as a potential treatment for gliomas with or without minimal toxicity.
Replication assay. We used TCID 50 assays to quantify the cytopathic effect in terms of viral titers. Virus yields were determined by titer in 293 cells at 10 days after the infection of U-87 MG with 10 MOI of the Ad5¢24 adenovirus. The Ad5¢24 titer was a million times higher than the initial dose with the U-87 MG lysates in two independent experiments. Flow cytometry. Flow cytometric analysis of DNA content of the two human glioma cell lines after adenoviral infection showed that the transfer of Ad5¢24 resulted in ≤8.5% of cells in sub-G1, 8 days and 5 days post-infection ( Fig. 3 ; representative experiment on U-87 MG and U-251 MG cells, respectively). At that point, the cytopathic effect was widespread. The majority of the cells detached from the dish and cellular debris was substantial. However, there was only a small cell population in the sub-G1 area. The discrepancy between the morphological and flow cytometric data suggests that the virus-mediated cell death was probably due to both cell lysis and apoptosis. Additionally, expression of the p53 protein induced apoptosis in about 12.1% of U-251 MG cells and <1.5% of U-87 MG cells (Fig. 3) . Our results on apoptosis in U-251 MG and U-87 MG cells after the adenoviral-mediated transfer of p53 agree with previous findings from our laboratory (4); the relatively small percentage of apoptotic cells in this study probably reflects the small adenoviral dose (20 MOI). U-251 MG cells overexpressing p53 and carrying the oncolytic Ad5¢24 at 10 MOI were apoptotic at a degree of 27.26%, but no apoptotic cell death was detected under the same conditions in U-87 MG cells according to flow cytometry data (Fig. 3) . The results obtained when U-251 MG cells were infected with both viruses (Ad5¢24 and Ad5CMV-p53) agree with previous reports that p53 can cooperate with other viral and cell proteins to enhance adenovirally mediated cell death (12) .
Discussion
Transferring a single gene for gene therapy for cancer may not be successful for several highly heterogeneous tumors e.g. glioblastomas (1) . Several approaches using the transfer of more than one gene have been published, and others are under investigation (13) (14) (15) . Conditionally replicative oncolytic viruses were also engineered as a second-step tool to adenoviral gene transfer therapy for cancer. Many reports suggest that this approach could be successful in the treatment of gliomas and other tumors (16) (17) (18) .
In the present study, we examined the effect of the combined oncolytic (Ad5¢24) adenovirus and apoptotic gene (p53) transfer in cultured glioma cells. Our results showed that co-infection of glioma cells with Ad5¢24 adenovirus and Ad5CMV-p53 adenovirus led to cell death by both apoptosis and cell lysis. The simultaneous use of both agents was effective, but each one alone did not inhibit the cytolytic or apoptotic action of the other. Thus, it appeared that the simultaneous presence of the two molecules tested here exerted an additive effect, even though each molecule exhibited its own death pathway. This finding suggests that p53 does not interfere with the capacity of Ad5¢24 to conditionally proliferate, a fact that was also observed in previous studies (12, 20) .
In summary, our results indicate that the combination of an adenovirus carrying the apoptosis-inducing p53 gene and a cytolytic adenovirus specific to cells with a defective p16/Rb/E2F pathway have an additive effect on cell death of gliomas in vitro. Even though in vivo experiments were not 
